ULTIBRO Breezhaler is indicated as maintenance bronchodilator therapy for adult patients with chronic obstructive pulmonary disease (COPD)—including chronic bronchitis and emphysema
It helps relieve symptoms and reduce exacerbations in patients with a history of COPD flare ups
Administer one capsule (110/50 /µg) via inhaler once daily, at the same time each day
Use the supplied Breezhaler device—do not swallow the capsule
If a dose is missed, take it as soon as you remember—only if same day. Do not take more than one capsule in 24 hours
Elderly (≥ /75 years): standard dose is acceptable
Renal impairment (mild–moderate): no adjustment needed; severe renal impairment or dialysis: use only if benefits outweigh risks
Mild–moderate hepatic impairment: use with caution; no data in severe hepatic impairment
Not for treatment of asthma or acute bronchospasm episodes (e.g., not a rescue inhaler)
Avoid in patients with hypersensitivity to components, galactose intolerance, or lactase deficiency
Use with caution in patients with narrow-angle glaucoma, urinary retention, cardiovascular diseases (e.g., arrhythmias, unstable ischemic heart disease), QT prolongation risks, and thyrotoxicosis or convulsive disorders
May cause hypokalaemia, hyperglycemia, and urinary retention; monitor accordingly in at risk patients
Store capsules below 30 /°C, in a dry place, shielded from moisture and light
Do not swallow capsules—use inhaler device only
Clean inhaler per instructions in package insert
Malaysia
